Marcos Rubio-Fernández

Dr. Marcos Rubio-Fernández


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
VPVICTOR BLANCO PALMERO
VICTOR BLANCO PALMERO
MRMarcos Rubio-Fernández
Marcos Rubio-Fernández
DADesireé Antequera
Desireé Antequera
AVAlberto Villarejo-Galende
Alberto Villarejo-Galende
JMJosé Antonio Molina
José Antonio Molina
Eva M. CarroEva M. Carro
Eva M. Carro
Neuroinflammation is a common feature in Alzheimer’s (AD) and Parkinson’s (PD) disease. In the last few decades, a testable hypothesis was proposed that protein-unfolding events might occur due to neuroinflammatory cascades involving alterations in the crosstalk between glial cells and neurons. Here, we tried to clarify the pattern of two of the most promising biomarkers of neuroinflammation in cerebrospinal fluid (CSF) in AD and PD. This study included cognitively unimpaired elderly patients, patients with mild cognitive impairment, patients with AD dementia, and patients with PD. CSF samples were analyzed for YKL-40 and C-reactive protein (CRP). We found that CSF YKL-40 levels were significantly increased only in dementia stages of AD. Additionally, increased YKL-40 levels were found in the cerebral orbitofrontal cortex from AD patients in agreement with augmented astrogliosis. Our study confirms that these biomarkers of neuroinflammation are differently detected in CSF from AD and PD patients.